Sprung-Navigation
Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M, Eckart MJ,
Kranz G, Goede V, Elter T, Bühler A, Winkler D, Kneba M, Döhner H, Eichhorst BF, Hallek M, Wendtner CM
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia:
a multicenter phase II trial of the german chronic lymphocytic leukemia study group
J Clin Oncol. 2011 Sep 10;29(26):3559-66
Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M; ESMO Guidelines Working Group
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol. 2011 Sep;22 Suppl 6:vi50-4
Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M
Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis
Blood. 2011 Feb 10;117(6):1817-21
Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M, Sobh M, Choquet S, Corront B, Dearden C, Gratwohl A, Herr W, Catovsky D, Hallek M, de Witte T, Niederwieser D, Leporrier M, Milligan D
Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation
Blood. 2011 Feb 3;117(5):1516-21
Cramer P, Hallek M.
Prognostic factors in chronic lymphocytic leukemia-what do we need to know?
Nat Rev Clin Oncol. 2011 Jan;8(1):38-47. Review
Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S
TP53 mutation and survival in chronic lymphocytic leukemia
J Clin Oncol. 2010 Oct 10;28(29):4473-9
Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, HasenkampJ, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek M,Kneba M, Schmitz N, Stilgenbauer S.
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X trial
Blood. 2010 Oct 7;116(14):2438-47
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group.
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Lancet. 2010 Oct 2;376(9747):1164-74
Schweighofer CD, Wendtner CM.
First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
Onco Targets Ther. 2010 Jun 24;3:53-67
Hallek M.
State-of-the-art treatment of chronic lymphocytic leukemia
Hematology Am Soc Hematol Educ Program. 2009:440-9. Review
Dreger P.
Allotransplantation for chronic lymphocytic leukemia
Hematology Am Soc Hematol Educ Program. 2009:602-9. Review.
Böttcher S, Stilgenbauer S, Busch R, Brüggemann M, Raff T, Pott C, Fischer K, Fingerle-Rowson G, Döhner H, Hallek M, Kneba M, Ritgen M.
Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patientsafter rituximab-containing immunochemotherapy: a comparative analysis
Leukemia. 2009 Nov;23(11):2007-17
Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, Kranzhofer N, Rohrberg R, Soling U, Burkhard O, Westermann A, Goede V, Schweighofer CD, Fischer K, Fink AM, Wendtner CM, Brittinger G, Dohner H, Emmerich B, Hallek M; German CLL Study Group (GCLLSG)
First line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
Blood 2009 Oct 15;114(16):3382-91
Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, Sarno A, Groner S, Mertens D, Busch R, Hallek M, Döhner H, Stilgenbauer S
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial
Blood. 2009 Sep 24;114(13):2589-97
Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H; German Chronic Lymphocytic Leukemia Study Group
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group
J Clin Oncol. 2009 Aug 20;27(24):3994-4001
Eichhorst B, Goede V, Hallek M.
Treatment of elderly patients with chronic lymphocytic leukemia
Leuk Lymphoma. 2009 Feb;50(2):171-8
Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt W, Kneba M, Hallek M, Wendtner CM
Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)
Br J Haematol. 2009 Jan;144(1):95-8
Ritgen M, Böttcher S, Stilgenbauer S, Bunjes D, Schubert J, Cohen S, Humpe A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P; German CLL Study Group
Quantitative MRD monitoring identifies distinct GVLresponse patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial
Leukemia. 2008 Jul;22(7):1377-86
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia.
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:
a report from the InternationalWorkshop on Chronic Lymphocytic Leukemia
updating the National Cancer Institute–Working Group 1996 guidelines
Blood. 2008 Jun 15;111(12):5446-56
(Erratum in Blood. 2008 Dec 15;112(13):5259)
Hallek M; German CLL Study Group
Prognostic factors in chronic lymphocytic leukemia
Ann Oncol. 2008 Jun;19 Suppl 4:iv51-3
Eichhorst BF, Busch R, Stauch M, Bergmann M, Ritgen M, Kranzhöfer N, Schweighofer CD, Fischer K, Fink A-M, Cramer P, Goede V, Wendtner CM, Hallek M, GCLLSG
No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG)
Blood (ASH Annual Meeting Abstracts) 2007 Nov; 110(11): Abstract #629
Eichhorst BF, Busch R, Obwandner T, Kuhn-Hallek I, Herschbach P, Hallek M; German CLL Study Group.
Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group
J Clin Oncol. 2007 May 1;25(13):1722-31
Eichhorst BF, Busch R, Schweighofer C, Wendtner CM, Emmerich B, Hallek M; German CLL Study Group (GCLLSG).
Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy
Br J Haematol. 2007 Jan;136(1):63-72
Bilban M, Heintel D, Scharl T, Woelfel T, Auer MM, Porpaczy E, Kainz B, Krober A, Carey VJ, Shehata M, Zielinski C, Pickl W, Stilgenbauer S, Gaiger A, Wagner O, Jager U; German CLL Study Group.
Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression
Leukemia. 2006 Jun;20(6):1080-8
Moosig F, Schoch R, Kneba M.
Die T-Large Granular Lymphocyte Leukämie (T-LGL-Leukämie): Eine wichtige Differenzialdiagnose zum Felty-Syndrom
Z Rheumatol. 2006; 65(6): 447 - 451
Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jager U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Dohner H, Brittinger G, Emmerich B, Hallek M; German CLL Study Group.
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
Blood 2006; 107(3): 885 - 891
Bergmann MA, Goebeler ME, Herold M, Emmerich B, Wilhelm M, Ruelfs C, Boening L, Hallek MJ; German CLL Study Group
Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group
Haematologica. 2005 Oct;90(10):1357-64
Heintel D, Kienle D, Shehata M, Krober A, Kroemer E, Schwarzinger I, Mitteregger D, Le T, Gleiss A, Mannhalter C, Chott A, Schwarzmeier J, Fonatsch C, Gaiger A, Dohner H, Stilgenbauer S, Jager U.
High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia
Leukemia 2005; 19: 1216 - 1223
Heintel D, Kroemer E, Kienle D, Schwarzinger I, Gleiss A, Schwarzmeier J, Marculescu R, Le T, Mannhalter C, Gaiger A, Stilgenbauer S, Dohner H, Fonatsch C, Jager U; German CLL Study Group.
High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia
Leukemia 2004; 18(4): 756 - 62
Dreger P; German CLL Study Group; EBMT.
Transplantation strategies in chronic lymphocytic leukemia: current concepts of the German CLL Study Group and the EBMT
Ann Hematol. 2004; 83 Suppl 1: S68 - 70
Hallek M, Eichhorst BF
Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia
Hematol J. 2004; 5 Suppl 1: S20 - 30
Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G, Eichhorst B, Busch R, Diem H, Engert A, Stilgenbauer S, Dohner H, Kneba M, Emmerich B, Hallek M; German CLL Study Group (GCLLSG)
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
Leukemia. 2004; 18(6): 1093 - 101
Hallek M, Bergmann M, Emmerich B
Chronic lymphocytic leukaemia: up-dated recommendations on diagnosis and treatment
Onkologie. 2004; 27(1): 97 - 104
Dreger P, Stilgenbauer S, Benner A, Ritgen M, Krober A, Kneba M, Schmitz N, Döhner H.
The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status
Blood 2004; 103(7): 2850 - 2858
Hallek M, Bergmann M, Goede V, Fingerle-Rowson G, Schweighofer C, Schmitt B, Wendtner CM, Emmerich B
Current concepts in chronic lymphocytic leukemia. Better chances for young patients
MMW Fortschr Med. 2003; 145(27-28): 46-9
Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, Aulitzky WE, Hensel M, Herold M, Huhn D, Hallek M, Diehl V, Engert A; German CLL Study Group
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia
Blood. 2002 Nov 1;100(9):3115-20
Schmitt B, Wendtner CM, Bergmann M, Busch R, Franke A, Pasold R, Schlag R, Hopfinger G, Hiddemann W, Emmerich B, Hallek M
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia
Clin Lymphoma. 2002; 3(1): 26 - 35
Hallek M, Bergmann M, Emmerich B für die Deutsche CLL-Studiengruppe
Chronische lymphatische Leukämie: Aktualisierte Vorschläge zu Diagnostik und Therapie
Dt. Ärzteblatt 2002; Jg.99 (Heft 19): A 1294 - A1301
Stilgenbauer S, Bullinger L, Lichter P and Döhner H. and the German CLL Study Group
Genetics of chronic lymphotic leukemia: genomic aberrations and VH gene mutation status in pathogenesis andclinical course
Leukemia 2002; 16(6): 993 - 1007
Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B; German Chronic Lymphocytic Leukemia Study Group
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
Blood. 2001 Sep 1;98(5):1326-1331
Hallek M, Schmitt B, Wilhelm M, Busch R, Krober A, Fostitsch HP, Sezer O, Herold M, Knauf W, Wendtner CM, Kuse R, Freund M, Franke A, Schriever F, Nerl C, Dohner H, Thiel E, Hiddemann W, Brittinger G, Emmerich B; German Chronic Lymphocytic Leukaemia Study Group
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group
Br J Haematol. 2001 Aug;114(2):342-348
Hallek M, Buening H, Ried M, Hacker U, Kurzeder C, Wendtner CM
Grundlagen der Gentherapie -Prinzipien und Stand der Entwicklung
Internist 2001; 42(10): 1306 - 1313
von Bubnoff N, Adler S, Danhauser-Riedl S, Kamp T, Nerl C, Emmerich B, Hallek M
The activation of intracellular tyrosine kinases by interferon-alpha (IFNalpha) correlates with its antiproliferative activity in B-lymphoid cell lines, but not in B-cell chronic lymphocytic leukaemia patients
Ann Hematol 2000; 79(3): 119-126
Wendtner CM, Schmitt B, Wilhelm M, Dreger P, Montserrat E, Emmerich B, Hallek M
Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk-adapted therapy
Ann Oncol. 1999; 10(5): 505 - 509
Meinhardt G, Wendtner CM, Hallek M
Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival
J Mol Med 1999; 77(2): 282 -293
Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M
CD40-Activated B-Cell Chronic Lymphocytic Leukemia Cells for Tumor Immunotherapy: Stimulation of Allogeneic Versus Autologous T Cells Generates Different Types of Effector Cells
Blood 1999; 93(6): 1992 - 2002
Hallek M, Langenmayer I, Nerl C, Knauf WU, Dietzfelbinger H, Adorf D, Ostwald M, Busch R, Kuhn-Hallek I Thiel E, Emmerich B
Elevated serum thymidine kinase levels identify a subgroup at high risk of disease-progressionin early, non-smoldering chronic lymphocytic leukemia.
Blood 1999; 93(5): 1732 - 1737
Hallek M, Kuhn-Hallek I, Emmerich B
Prognostic factors in chronic lymphocytic leukemia.
Leukemia 1997; 11 (Suppl.2): S4 - S13
Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S, Schick H-D, Kuhn-Hallek I, Emmerich B
Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progressionfree survival in chronic lymphocytic leukemia and immunocytoma.
Leuk Lymphoma 1996; 22(5-6): 439 - 447
Langenmayer I, Knauf W, Nerl C, Dempster S, Hallek M, Adorf D, Dietzfelbinger H, Busch R, Ziegler-Heitbrock HWL, Thiel E, Emmerich B
Interferon-alpha-2b (IFN alpha) for early-phase lymphocytic leukemia with high risk disease-progression: results of a randomized multicenter study.
Br J Haematol. 1996; 94(2): 362 - 369